Turning Question Marks Into Check Marks: HHS Blueprint One Year Later
Direct-to-consumer ad rule is first of a series of high-profile regulations aimed at lowering drug prices and reducing out-of-pocket costs that the Trump Administration hopes to implement by 2020.
You may also be interested in...
A series of abstracts highlight the impact of the ACA and Medicaid expansion on ovarian cancer diagnosis, racial disparities in time to treatment and the impact of insurance type on myeloma survival.
Nevertheless, the Pharmaceutical Research and Manufacturers of America announces enhancement of its drug pricing disclosures voluntary program, a Medicines Assistance Tool website that links to individual company sites, in response to the US rule.
The reform 'blueprint' might actually live up to its hype.